• FY27 Financial Guidance: Despite Q1 drag from depreciation and operational expenses in new businesses, management expects commercial milestones in H2 to drive consolidated full-year revenue growth of 20–25% and EBITDA growth above 25%, targeting EBITDA margins close to 30%.
• Biotech CDMO Expansion: Following over ₹400 crore in capex for fermentation-based capabilities, commercial revenues are slated to begin in Q4 FY27 and scale in FY28, aiming for >70% gross margins, >35% EBITDA margins, and ₹300–400 crore in revenue over the next three years.
• US FDA Inspections: Symbiotec has successfully cleared three audits across its Rau and Pithampur SEZ facilities with EIRs in place. A fourth recent audit received four procedural observations, with EIR clearance anticipated within two to three months.